Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna

The group that developed a Covid jab using messenger RNA (mRNA) technology has inked a US$250mln deal with to create a cancer vaccine with one of the world's largest pharma companies. Moderna Theraputics Inc is teaming up with Merck to develop and commercialise the personalised cancer drug mRNA-4157/V940, which is currently in phase II trials.

Moderna and Merck ink US$250mln deal to develop world's first cancer vaccine

The move is welcomed by investors because if successful, it would help Moderna diversify its revenue and profits away from COVID-19 vaccines.

Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine

Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.

Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients

Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed. The post Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment appeared first on Investor's Business Daily.

Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment

Merck & Co. Inc. MRK, +0.63% and Moderna Inc. MRNA, -2.19% said Wednesday that they plan to jointly develop and commercialize a personalized cancer vaccine. The investigational vaccine is currently being tested in a Phase 2 clinical trial as a treatment for patients with high-risk melanoma in combination with Merck's Keytrduda, an anti-PD-1 therapy that has been approved to treat several types of cancer.

Merck, Moderna to develop personalized cancer vaccine

Merck & Co Inc opted to jointly develop and potentially sell a personalized mRNA vaccine with Moderna Inc for a $250 million upfront payment on Wednesday, sending the vaccine maker's shares up over 8%.

Merck opts to develop, sell cancer vaccine with Moderna

Bank of America

DTE Energy

NRG Energy

PepsiCo

Republic Services

Constellation Brands

Walmart

Unless you are an incredible market-timer and stock trader, making money this year has been almost impossible.

8 Goldman Sachs Conviction List Dividend Stocks May Be the Safest Q4 Plays Now

Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022 CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / October 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement. mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna.

Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine

Chevron

Exxon Mobil

These stocks could add to Buffett's fortune by the end of 2022.

3 Dividend Stocks in Warren Buffett's Secret Portfolio Most Likely to Soar in Q4

Amgen

Johnson & Johnson

3 Dow Jones Stocks to watch in the stock market in October 2022.

Best Stocks To Buy Right Now? 3 Dow Jones Stocks To Watch

Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.

Merck (MRK) Posts Positive Results From PAH Drug Study

Merck could be sitting on a blockbuster from a recent acquisition that would help reduce dependence on cancer drug Keytruda.

Merck's Patent Cliff Doesn't Look So Frightening Anymore

There is more to the comparison, and in the sections below, we discuss why we believe MRK stock will offer better returns than LLY stock in the next three years.

Merck Stock Is Likely A Better Pick Over Its Peer

Merck has demonstrated resilience in the current macroeconomic environment. MRK has a strong portfolio of drugs, and Keytruda keeps expanding its use cases.

Merck: Resilient To Macroeconomic Headwinds, Attractively Valued

Despite a rough day outing on Monday for the major equity indices, shares of pharmaceutical giant Merck (NYSE: MRK ) swung higher. Early this morning, the company announced positive top-line results from a Phase 3 study involving sotatercept, an investigational fusion protein evaluated for the treatment of pulmonary arterial hypertension (PAH).

Merck (MRK) Stock Jumps 4% on Positive Trial Data

Apple

Caterpillar

Liberty Oilfield Services

McDonald's

Microsoft

Travelers

Select Energy Services

Two new Breakout Stocks for Week 41 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +106.5% YTD. This week one pick beat 10% in less than a week with ZYME at 10.84% peak gains despite high negative Momentum Gauge warnings.

MDA Breakout Stocks Week 41- October 2022: Short-Term Picks To Give You An Edge

Merck stock jumped Monday after a drug its acquired for billions scored a "must-win" in patients with a rare blood pressure condition. The post Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout appeared first on Investor's Business Daily.

Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been named to Fortune's 2022 Change the World list. The annual list recognizes companies that have had a positive social impact through activities that are part of their core business strategy. Merck was selected for its work expanding global access to the company's human papillomavirus (HPV) vaccines. “It's an honor for Merck to be included on Fortune's 2022 Change the World List, and recog

Merck Recognized on Fortune's 2022 Change the World List for Expanding Access to HPV Vaccines

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1). The trial met its primary efficacy outcome measure, dem

Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)

ISSOIRE, France--(BUSINESS WIRE)-- #digitalhealth--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck KGaA, Darmstadt, Germany, a leading science, and technology company, have entered into an agreement for the development and supply of a specific version of Mallya device as an accessory for one of Merck KGaA, Darmstadt, Germany's drug delivery devices. Manufactured i

BIOCORP and Merck KGaA, Darmstadt, Germany, Sign a New Partnership for Smart Drug Delivery

Accenture Plc

Cisco Systems

Mastercard

Procter & Gamble

Visa

After two months off, I'm back with another edition of my monthly series, 10 Dividend Growth Stocks. I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks For October 2022

AbbVie

Their dividends should be much bigger in the future.

3 Great Dividend Stocks to Buy in October

RAHWAY, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Alphabet

Eli Lilly

NVIDIA

September has historically been the weakest month for the U.S. stock market, and 2022 was no different.

These Were The Five Best And Worst Performing Mega-Cap Stocks In September 2022

UnitedHealth Group

Apple and Microsoft are among the Dow Jones stocks to watch in October. The post 5 Dow Jones Stocks To Watch In October: Apple Rebounds appeared first on Investor's Business Daily.

News for Merck Stock (MRK)